May 8, 2018 / 11:38 AM / 13 days ago

BRIEF-Oncosec Expands Relationship With Merck For Combination Of Immunopulse Il-12 And Keytruda

May 8 (Reuters) - OncoSec Medical Inc:

* ONCOSEC EXPANDS RELATIONSHIP WITH MERCK, ANNOUNCES CLINICAL COLLABORATION TO EVALUATE COMBINATION OF IMMUNOPULSE IL-12 AND KEYTRUDA FOR TRIPLE NEGATIVE BREAST CANCER

* ONCOSEC MEDICAL - PLANNED TRIAL WILL EVALUATE SAFETY, EFFICACY OF COMBINATION IN CERTAIN PATIENTS WITH INOPERABLE LOCALLY ADVANCED OR METASTATIC TNBC

* ONCOSEC MEDICAL SAYS UNDER COLLABORATION AGREEMENT, ONCOSEC WILL SPONSOR, FUND STUDY AND MERCK WILL PROVIDE KEYTRUDA

* ONCOSEC MEDICAL SAYS ADDITIONAL DETAILS OF THE COLLABORATION WERE NOT DISCLOSED Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below